newsfilter
← Latest News
ACCESS Newswire·

Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate

Company's host-directed therapeutic, EB05 , demonstrated a statistically significant mortality reduction among critically ill patients with severe respiratory diseaseTORONTO, ON / ACCESSWIRE / September